FTHL17

Across TCGA pan-cancer cohorts, FTHL17 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FTHL17 data layer compared with 18 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FTHL17 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FTHL17 expression acts as an unfavorable survival marker.

CCRCC are the cancer types where FTHL17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.717	1.000	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

FTHL17–CCRCC (OS)

Open the CCRCC breakdown →